Arrien is committed to the proper identification, quality, purity, and strength of the pre-clinical or investigational drug and to assure that it is reasonably safe to conduct the proposed clinical investigations. We are fully committed to establish the efficacy and safety of an IND candidate for use in humans, in a dose range and schedule that provides an acceptable risk benefit relationships, which are critical to Arrien drug development process.